United States Spices and Seasonings Market Size Projected to Reach USD 13,234.1 Million by 2034 with a CAGR of 6.48%

IMARC Group has recently released a new research study titled “United States Nuclear Imaging Market Size, Share, Trends and Forecast by Product, Application, and Region, 2026-2034,” offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

United States Nuclear Imaging Market Size, Growth, and Forecast (2026-2034)

The united states nuclear imaging market reached USD 3.2 Billion in 2025 and is projected to reach USD 4.5 Billion by 2034, growing at a CAGR of 3.66% during 2026-2034. Rising prevalence of chronic diseases including cancer and cardiovascular disorders, increasing adoption of hybrid imaging technologies, and advancements in radiopharmaceuticals for personalized medicine are the primary factors driving the us nuclear imaging devices market.

• Base Year: 2025
• Forecast Period: 2026-2034
• Historical Period: 2020-2025
• Market Size in 2025: USD 3.2 Billion
• Market Forecast in 2034: USD 4.5 Billion
• Market Growth Rate (2026-2034): 3.66%

Nuclear imaging, also known as molecular imaging, encompasses positron emission tomography (PET) and single photon emission computed tomography (SPECT) technologies used to visualize physiological processes at the cellular and molecular level. These modalities rely on radiopharmaceuticals such as technetium-99m and fluorine-18 to enable early and precise diagnosis across oncology, cardiology, and neurology applications.

Growing geriatric population demographics, increasing healthcare expenditure, and technological advancements in hybrid PET/CT and SPECT/CT systems continue to expand diagnostic capabilities across the us nuclear imaging devices market. FDA support for innovative diagnostics and accelerating integration of artificial intelligence into imaging workflows are further reshaping how providers approach early disease detection.

Get Insights on the United States Nuclear Imaging Market- Access the IMARC Sample Report: https://www.imarcgroup.com/united-states-nuclear-imaging-market/requestsample

Key Trends Driving the United States Nuclear Imaging Market

• Increasing adoption of hybrid imaging technologies: PET/CT and SPECT/CT systems combine the functional imaging strength of nuclear medicine with the anatomical precision of CT, and rising chronic disease burden, with about 129 million Americans living with at least one major chronic condition, continues to drive demand for these hybrid modalities.
• Rising demand for radiopharmaceuticals in personalized medicine: FDG and technetium-based compounds are increasingly central to targeted diagnostics in oncology and neurology, with expanded manufacturing capacity supporting faster, more localized access to novel tracers.
• AI integration across imaging workflows: Artificial intelligence is improving image analysis, reducing scan times, and minimizing radiation exposure, helping healthcare organizations optimize diagnostic accuracy and operational efficiency across the us nuclear imaging devices market.

United States Nuclear Imaging Market Report Segmentation:

The market has been segmented based on product and application, offering comprehensive insights across the us nuclear imaging devices market.

Product Insights:

•      Equipment

•      Radioisotope

The product landscape includes equipment covering SPECT radioisotopes (technetium-99m, thallium-201, gallium-67, iodine, and others) and radioisotope offerings covering PET radioisotopes (fluorine-18, rubidium-82, and others), each serving distinct diagnostic and imaging protocols.

Application Insights:

•      SPECT Applications

•      PET Applications

Oncology remains the leading PET application given the modality's precision in detecting and staging cancer, while cardiology spans both SPECT and PET use cases for perfusion imaging, and orthopedics and thyroid imaging continue to anchor established SPECT applications.

Regional Insights:

•      Northeast

•      Midwest

•      South

•      West

The Northeast benefits from a dense concentration of academic medical centers and cancer treatment facilities driving early adoption of advanced imaging, while the South and West are expanding capacity through new radiopharmaceutical manufacturing and cyclotron infrastructure, and the Midwest continues to build out hybrid imaging access across regional hospital networks.

United States Nuclear Imaging Market: Recent News and Developments

• June 2025: GE HealthCare showcased its advanced molecular imaging solutions, including the Flyrcado PET myocardial perfusion tracer, at the SNMMI annual meeting in New Orleans, with the tracer launched in select U.S. markets the same month to support earlier diagnosis and more personalized cardiac treatment.
• November 2025: Siemens Healthineers rebranded its PET radiopharmaceutical businesses, PETNET Solutions and Advanced Accelerator Applications, under the unified Siemens Healthineers name, consolidating a network of 60 radiopharmaceutical manufacturing facilities across the U.S. and Europe into a single Radiopharma business segment.

Challenges Impacting the United States Nuclear Imaging Market

Stringent regulatory requirements and lengthy approval pathways for new radiopharmaceuticals and imaging equipment can slow the pace at which innovative diagnostics reach clinical practice.

High equipment costs and complex, time-sensitive supply chain logistics for short-half-life radioisotopes create operational and financial barriers, particularly for smaller imaging centers seeking to expand nuclear imaging capabilities.

Investment Opportunities in the United States Nuclear Imaging Market

The us nuclear imaging devices market presents compelling investment opportunities supported by its projected growth from USD 3.2 Billion in 2025 to USD 4.5 Billion by 2034. Expanding theranostic applications, which combine diagnostic imaging with targeted radiotherapy, represent a high-value opportunity as precision oncology continues to scale.

AI-powered diagnostic enhancement and continued build-out of domestic radiopharmaceutical manufacturing capacity offer additional investment frontiers, particularly as providers seek to reduce reliance on imported isotopes and improve supply chain resilience.

Outlook of the United States Nuclear Imaging Market (2026-2034)

The outlook for the United States nuclear imaging market is positive, supported by rising chronic disease prevalence, an aging population, and continuous innovation in hybrid imaging and radiopharmaceuticals. The market is projected to grow from USD 3.2 Billion in 2025 to USD 4.5 Billion by 2034 at a CAGR of 3.66%.

Continued expansion of theranostic approaches, growing molecular imaging applications, and deeper AI integration will be the defining trends shaping the us nuclear imaging devices market through 2034.

Key Players in the United States Nuclear Imaging Market

The United States nuclear imaging market is served by a mix of global medical imaging leaders and specialized radiopharmaceutical manufacturers competing on the basis of technology innovation, FDA approvals, and manufacturing scale.

• GE HealthCare:

A global leader in molecular imaging, GE HealthCare continues to expand its diagnostic portfolio with hybrid PET/CT systems such as the Omni Legend, manufactured domestically in Waukesha, Wisconsin, alongside novel radiopharmaceutical tracers designed to improve early diagnosis and personalized treatment planning.

• Siemens Healthineers:

The world's largest manufacturer and distributor of PET radiopharmaceuticals, Siemens Healthineers operates 60 radiopharmaceutical facilities across the U.S. and Europe through its consolidated Radiopharma business segment, supplying agents used in oncology, cardiology, and neurological diagnostics.

Frequently Asked Questions (FAQs): United States Nuclear Imaging Market

1. What is the current United States nuclear imaging market size?

The United States nuclear imaging market size reached USD 3.2 Billion in 2025 and is projected to reach USD 4.5 Billion by 2034, growing at a CAGR of 3.66% during 2026-2034.

2. What is nuclear imaging?

Nuclear imaging, also called molecular imaging, includes PET and SPECT technologies that use radiopharmaceuticals to visualize physiological processes for diagnosing conditions such as cancer, cardiovascular disease, and neurological disorders.

3. What are the key drivers of the us nuclear imaging devices market?

Key drivers include rising prevalence of chronic diseases such as cancer and cardiovascular disorders, increasing adoption of hybrid imaging technologies, advancements in radiopharmaceuticals, aging populations, and AI integration in imaging systems.

4. Which product segment leads the United States nuclear imaging market?

Equipment, including SPECT and PET radioisotope-compatible systems, forms a core component of the market alongside radioisotope offerings such as fluorine-18 and technetium-99m used across diagnostic applications.

5. Who are the key players in the United States nuclear imaging market?

Key players in the United States nuclear imaging market include GE HealthCare and Siemens Healthineers, alongside other global imaging and radiopharmaceutical manufacturers such as Cardinal Health.

Author IMARC Group

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

United States: +1-201971-6302